An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance
PDL BioPharma (United States) · Roche (Canada) · +3 more institutions
Abstract
The Hippo pathway is a key growth control pathway that is conserved across species. The downstream effectors of the Hippo pathway, YAP (Yes-associated protein) and TAZ (transcriptional coactivator with PDZ-binding motif), are frequently activated in cancers to drive proliferation and survival. Based on the premise that sustained interactions between YAP/TAZ and TEADs (transcriptional enhanced associate domain) are central to their transcriptional activities, we discovered a potent small-molecule inhibitor (SMI), GNE-7883, that allosterically blocks the interactions between YAP/TAZ and all human TEAD paralogs through binding to the TEAD lipid pocket. GNE-7883 effectively reduces chromatin accessibility…
Citation impact
- FWCI
- 36.70
- Percentile
- 100%
- References
- 76
Authors
42Topics & keywords
- Hippo signaling pathway
- KRAS
- Allosteric regulation
- Biology
- Transcription factor
- Effector
- Cancer research
- Cell biology
- Life in Land